To examine the effect of Cebpb-targeted BMDCs on tumor development in vivo, B16 cells were injected subcutaneously, and five days later, gRNA-Cebpb or gRNA-NT BMDCs were injected into the tumor site (Fig. 2c, “Methods”). The gene discussed is CEBPB; the disease is neoplasm.